Bevacizumab 15mg/kg Therapy - 21 days. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Bevacizumab 15mg/kg Therapy - 21 days, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/215.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
In combination with PACLitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.	1
In combination with erlotinib is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous cell lung cancer with Epidermal Growth Factor (EGFR) activating mutations	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	HER2-negative	Invasive Breast Carcinoma	Bevacizumab, Paclitaxel
Sensitivity (+)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib